Appleby, N., O'Brien, D., Quinn, F. M., Smyth, L., Kelly, J., Parker, I., Scott, K., Cahill, M. R., Crotty, G., Enright, H., Hennessy, B., Hodgson, A., Leahy, M., O'Leary, H., O'Dwyer, M., Hayat, A., & Vandenberghe, E. A. (2018). risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL. Leukemia & lymphoma, 59(6), 1338–1347. http://access.bl.uk/ark:/81055/vdc_100064432671.0x000026